Defense against filoviruses used as biological weapons

被引:76
作者
Bray, M [1 ]
机构
[1] NIAID, Biodef Clin Res Branch, OCR,OD, NIH, Bethesda, MD 20892 USA
关键词
filovirus; ebola virus; marburg virus; biological warfare; bioterrorism; biodefense;
D O I
10.1016/S0166-3542(02)00200-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The filoviruses, Marburg and Ebola, are classified as Category A biowarfare agents by the Centers for Disease Control. Most known human infections with these viruses have been fatal, and no vaccines or effective therapies are currently available. Filoviruses are highly infectious by the airborne route in the laboratory, but investigations of African outbreaks have shown that person-to-person spread requires direct contact with virus-containing material. In consequence, filovirus epidemics can be halted by isolating patients and instituting standard infection control and barrier nursing procedures. The filovirus disease syndrome resembles that caused by other hemorrhagic fever viruses, necessitating studies in a biocontainment laboratory to confirm the diagnosis. Some progress has been made in developing vaccines and antiviral drugs, but efforts are hindered by the limited number of maximum containment laboratories. Terrorists might have great difficulty acquiring a filovirus for use as a weapon, but my attempt to do so because of the agents' ability to inspire fear. Accurate information is the best tool to prevent panic in the event of an attack. Published by Elsevier Science B.V.
引用
收藏
页码:53 / 60
页数:8
相关论文
共 65 条
[1]  
ALI J, 1999, JANES CHEM BIOL DEFE
[2]  
Alibek K., 1999, BIOHAZARD
[3]   The Ebola virus VP35 protein functions as a type IIFN antagonist [J].
Basler, CF ;
Wang, XY ;
Mühlberger, E ;
Volchkov, V ;
Paragas, J ;
Klenk, HD ;
Garcia-Sastre, A ;
Palese, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12289-12294
[4]  
Belanov YF, 1996, VOP VIRUSOL+, V41, P32
[5]   Hemorrhagic fever viruses as biological weapons - Medical and public health management [J].
Borio, L ;
Inglesby, T ;
Peters, CJ ;
Schmaljohn, AL ;
Hughes, JM ;
Jahrling, PB ;
Ksiazek, T ;
Johnson, KM ;
Meyerhoff, A ;
O'Toole, T ;
Ascher, MS ;
Bartlett, J ;
Breman, JG ;
Eitzen, EM ;
Hamburg, M ;
Hauer, J ;
Henderson, A ;
Johnson, RT ;
Kwik, G ;
Layton, M ;
Lillibridge, S ;
Nabel, GJ ;
Osterholm, MT ;
Perl, TM ;
Russell, P ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (18) :2391-2405
[6]   A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever [J].
Bray, M ;
Davis, K ;
Geisbert, T ;
Schmaljohn, C ;
Huggins, J .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :651-661
[7]   3-deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice [J].
Bray, M ;
Raymond, JL ;
Geisbert, T ;
Baker, RO .
ANTIVIRAL RESEARCH, 2002, 55 (01) :151-159
[8]   Experimental therapy of filovirus infections [J].
Bray, M ;
Paragas, J .
ANTIVIRAL RESEARCH, 2002, 54 (01) :1-17
[9]   The role of the Type I interferon response in the resistance of mice to filovirus infection [J].
Bray, M .
JOURNAL OF GENERAL VIROLOGY, 2001, 82 :1365-1373
[10]   Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor [J].
Bray, M ;
Driscoll, J ;
Huggins, JW .
ANTIVIRAL RESEARCH, 2000, 45 (02) :135-147